Back Hepatitis C

Hepatitis C

July 28 Is World Hepatitis Day

July 28 is World Hepatitis Day, an opportunity to raise awareness about viral hepatitis and its consequences. This year's theme is "4000 Voices," reflecting the estimated 4000 people who die from viral hepatitis -- primarily hepatitis B and C -- each day, out of the approximately 400 million thought to be infected worldwide.

alt

IAS 2015: Fibrosis Regression Linked to Reduced Complications and Death in HIV/HCV Coinfected

HIV/HCV coinfected people with cirrhosis who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from liver-related causes -- and in some cases fibrosis regression is beneficial even in the absence of a cure -- according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver. A related study looked at predictors of liver fibrosis progression in HIV/HCV coinfected people, finding that use of certain NRTI "backbone"' antiretroviral drugs and HIV protease inhibitors may increase the risk.

alt

Updated Hepatitis C Care and Treatment Guidelines Published in Hepatology

The latest updated U.S. recommendations for hepatitis C testing, management, and treatment, compiled by an expert panel of members of the American Association for the Study of Liver Diseases (AASLD) and partner organizations, have been published in the June 25 advance online edition of Hepatology, the AASLD's professional journal.

alt

DDW 2015: Cirrhosis and Decompensation Are Common Among People with Chronic Hepatitis C

More than one-quarter of Kaiser-Permanente chronic hepatitis C patients developed cirrhosis over 12 years and 40% of these experienced decompensation -- rates higher than expected, according to a presentation at the recent Digestive Disease Week 2015 meeting in Washington, DC. The study also found that cirrhosis and decompensation were associated with comorbid conditions, supporting the idea of hepatitis C as a systemic disease.

alt

Hepatitis C Rising -- Especially Among Young People -- and May Be Underestimated

The Centers for Disease Control and Prevention (CDC) Division of Viral Hepatitis has released its 2013 Viral Hepatitis Surveillance Report, providing the latest data on hepatitis A, B, and C in the U.S. While hepatitis C has traditionally been predominant among Baby Boomers, the new report shows that HCV incidence is rising fastest among young people. But a recently published related study suggests that formal surveillance methods may grossly underestimate the number of people newly infected with HCV.

alt

FDA Approves Daclatasvir for Hepatitis C Genotype 3, Technivie for Genotype 4

The U.S. Food and Drug Administration has approved 2 new treatments for hepatitis C virus (HCV) genotypes 3 and 4, which account for millions of cases worldwide. Daclatasvir (Daklinza) received the nod for use in combination with sofosbuvir (Sovaldi) for hard-to-treat genotype 3, while AbbVie received approval for its 2D paritaprevir/ritonavir/ombitasvir coformulation for genotype 4. Options remain limited, however, for people with liver cirrhosis.

alt

Adding Ribavirin to Harvoni for Hepatitis C Increases Side Effects But Not Efficacy

Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone, according to an analysis of the Phase 3 ION trials described in the July edition of Hepatology.

alt

HIV-Negative Gay Men May Be Susceptible to Sexually Transmitted Hepatitis C

Several studies have shown that hepatitis C virus (HCV) can be sexually transmitted among HIV-positive men who have sex with men, but HIV-negative gay and bisexual men may be at risk as well if they share similar risk factors, according to a report in the June 2015 Journal of Viral Hepatitis.

alt

Viekira Pak Regimen Cures 100% of Genotype 1b Hepatitis C Patients with Cirrhosis

All participants in the TURQUOISE-III trial, which enrolled HCV genotype 1b patients with compensated liver cirrhosis, achieved sustained virological response using AbbVie's Viekira Pak or "3D" regimen without ribavirin, according to a company announcement this week.

alt